Basic Diltiazem Information

• INN (International Nonproprietary Name): Diltiazem
• Brand names available in Australia: Cardizem, Tildiem, Matzim
• ATC Code: C08DB01
• Forms & dosages: Tablets, injections, creams
• Manufacturers in Australia: Various, including Pfizer and Mylan
• Registration status in Australia: Prescription-only
• OTC / Rx classification: Rx

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Australian patients looking to purchase Diltiazem will find it readily available at major pharmacy chains such as Chemist Warehouse, Priceline, and TerryWhite Chemmart. These outlets offer a wide range of Diltiazem formulations, including tablets and topical creams, at competitive prices. The growing prominence of discount pharmacies in Australia significantly enhances access to essential medications. Therefore, price transparency becomes crucial for patients, enabling them to make informed choices when filling prescriptions.

Online Pharmacy Trends in Australia

The landscape of pharmacy in Australia is rapidly evolving with the rise of online options, allowing patients easier access to Diltiazem. Numerous reputable online pharmacies, many of which are registered e-pharmacies, provide convenient home delivery services. This trend is particularly beneficial for patients residing in regional areas or those who prefer the convenience of online shopping. Furthermore, the shift to e-prescriptions through telehealth services has solidified the growing popularity of online pharmacy platforms, making it easier than ever to obtain essential medications.

Price Ranges by Package Size (PBS vs Private)

When it comes to pricing, Diltiazem can vary significantly between Pharmaceutical Benefits Scheme (PBS) subsidised options and private purchases. For instance, the typical retail price for a 30 mg Diltiazem tablet can range from $20 to $50 in private pharmacies. However, for eligible patients, PBS prices can significantly reduce costs, making it crucial for consumers to understand their local pricing options. Awareness of eligibility for subsidies can empower patients to make informed decisions regarding their medication choices and financial planning.

Dosage & Administration

Understanding how to use diltiazem effectively can alleviate anxieties for those managing conditions like hypertension or angina. This section dives into dosage guidelines and special considerations based on individual patient needs.

Standard regimens

The standard dosage of diltiazem varies depending on the specific condition requiring treatment. For managing essential hypertension, initial recommendations suggest an oral dose of 120–240 mg daily, which is typically divided into two or three doses throughout the day. Patients dealing with chronic stable angina might require a higher daily intake, ranging from 180 to 360 mg. A convenient option for many is the extended-release formulation, allowing for once-daily dosing that can enhance adherence. It's crucial for healthcare providers to select the appropriate brand or formulation, as this choice can significantly influence the dosage schedule suited to each patient's unique health profile and circumstances.

Adjustments by patient type (elderly, chronic conditions)

Adjustments to the dosage are often necessary for certain patient groups, especially the elderly or those with additional chronic conditions. Older adults are generally advised to start on the lower end of the dosage spectrum due to an increased risk of side effects, such as hypotension and bradycardia. For patients with liver impairment, care must be taken as diltiazem's clearance may be hindered, potentially necessitating lower doses. In the case of renal impairment, a reduced dosage is typically not required unless there is severe dysfunction present. Regular follow-ups and thorough patient assessments are vital for ensuring effective dosing while minimising adverse effects. This ongoing vigilance aids in adapting treatment plans to meet individual patient needs.

Current Research & Trends

Understanding the current trends and research surrounding diltiazem can help both patients and healthcare providers make more informed decisions. Recent studies have not only emphasised diltiazem's traditional applications in cardiovascular health but are also probing into its off-label uses.

Major studies 2022–2025 (Australia + international)

The efficacy of diltiazem is currently being evaluated through numerous studies conducted by both Australian institutions and international research teams.

One focus area is its effectiveness in managing arrhythmias. Researchers are delving into how diltiazem affects heart rate control and its impact on long-term outcomes in patients with hypertension. Recent randomised controlled trials (RCTs) have shown promising results, particularly concerning diltiazem’s role in combination therapy for patients with resistant hypertension.

• Patient selection and monitoring are crucial for achieving optimal therapeutic outcomes in these situations.
• Diltiazem is being explored in integrated care settings, specifically its compatibility with telehealth approaches for prescription renewals and educational initiatives targeting patients with chronic conditions.

Researchers are evaluating newer formulations and delivery methods of diltiazem to find best practices in administration and adherence. They're also striving to uncover mechanistic insights which may aid in optimising cardiovascular health outcomes, particularly in diverse patient populations.

Understanding diltiazem's broader therapeutic potential is essential as healthcare continues to evolve. The ongoing investigations into its off-label uses are not only promising but reflect a shift towards more personalised healthcare solutions.

Product Information

Diltiazem, identified by its International Nonproprietary Name (INN), is recognised globally for its importance in prescribing and pharmacovigilance purposes. It comes in various brand names depending on the region, including:

• Cardizem® (United States)
• Tildiem® (United Kingdom/Ireland)
• Angizem® (Japan)
• Diltiazem Terapia® (Romania/Moldova)

The medication classifies as a calcium channel blocker and is primarily used for treatment in cardiovascular diseases. Available forms include oral tablets, extended-release capsules, and even injectable options. Standard dosages for conditions like essential hypertension generally range from 120–240 mg per day.

Common Side Effects

While diltiazem is widely used, its side effects should not be overlooked. Patients may experience mild to moderate reactions including:

• Edema (particularly in the ankles and feet)
• Headaches and dizziness
• Nausea and gastrointestinal upset
• Bradycardia and fatigue

These effects are often manageable but require monitoring, especially in elderly patients or those with additional health conditions.

Delivery Information